Streetbeat News

Revenues

LVO

LiveOne has reaffirmed its fiscal year 2025 revenue guidance, maintaining it at $140 million to $155 million, compared to analysts' expectations of $148.884 million.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:58 pm

LGCB

Linkage Global Inc's subsidiary, HQT Network, has signed a $40M advertising deployment contract with a client. The services include support for the client's advertising account and advertisement campaign services.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:43 pm

EEIQ

EpicQuest Education Group International Ltd (EEIQ) announced that its EduGlobal College has received approval for two new co-op programs, significantly expanding its academic offerings. The PTIB-approved programs have tripled, and all academic programs have seen a 50% increase.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:18 pm

NTRA

Natera, Inc. (NASDAQ:NTRA), a leader in cell-free DNA and genetic testing, announced surpassing 200 peer-reviewed publications featuring its technology. These publications, in top journals like Science and NEJM, cover Natera's advancements in women's health, oncology, and organ health, demonstrating its commitment to evidence-based innovations that improve patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:08 pm

BRAG

Bragg Gaming Group Inc. (BRAG) has entered into an international distribution agreement with Light & Wonder to feature Bragg's online casino content on Light & Wonder's ecosystem. This deal includes games from Bragg's proprietary studios and exclusive content from its Powered by Bragg partners, expanding Bragg's reach in European, USA, and Canadian markets. The collaboration aims to enhance Bragg's game exposure and strengthen its casino offering with new titles.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:07 pm

INMB

INmune Bio, Inc. (NASDAQ:INMB) has announced a registered direct offering, raising approximately $4.8 million in gross proceeds. The offering involves the sale of 571,592 shares of common stock at $8.32 per share, with warrants exercisable at $9.152, a 10% premium. Officers, employees, and directors purchased about 20% of the offering. The proceeds will fund Phase 2 trials for Alzheimer's and prostate cancer treatments. The offering is expected to close on April 24, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:06 pm

OCGN

Ocugen (NASDAQ:OCGN) has received consistent bullish ratings from 4 analysts over the past quarter, with a recent update showing an average 12-month price target of $6.5, marking a 44.44% increase from the previous target of $4.50. Analysts from Chardan Capital and HC Wainwright & Co. have raised their price targets, indicating a positive outlook on the company's performance. Ocugen's financial performance shows a significant revenue growth of 142.6% over the past 3 months, despite a lower market capitalization and challenges in net margin, ROE, and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:01 pm

FRT

Federal Realty Investment (NYSE:FRT) received mixed analyst ratings with a trend towards bullishness, as evidenced by 7 analysts' ratings. The average 12-month price target is $111.71, reflecting a slight increase from the previous target. Analyst actions include both upgrades and downgrades, with price targets ranging from $101.00 to $124.00. Federal Realty Investment Trust focuses on high-quality retail properties in major metropolitan markets, showing a revenue growth of 4.2% but below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:01 pm

RARE

Ultragenyx Pharmaceutical (NASDAQ:RARE) received mixed analyst ratings with a recent shift towards a more bullish outlook. The average 12-month price target is now $82.55, up 6.93% from the previous $77.20. Analyst actions include ratings from 'Outperform' to 'Neutral' with price targets ranging from $48.00 to $114.00. The company's financials show a positive revenue trend with a 23.27% growth rate, but it faces challenges with a net margin of -96.7%, ROE of -80.22%, and ROA of -9.03%. Its debt-to-equity ratio of 0.16 indicates lower reliance on debt financing.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:00 pm

KEX

Kirby Corp (NYSE:KEX) has received mixed analyst ratings over the past three months, with a recent shift towards a more bullish outlook. The latest evaluations from four analysts show an increase in the 12-month price target to an average of $116.00, up from $100.00, indicating a positive sentiment shift. Kirby, a leading domestic tank barge operator, has shown notable revenue growth of 9.45% as of December 31, 2023, but faces challenges in profitability and efficiency, with below-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:00 pm